ORCID Profile
0000-0002-4771-2617
Current Organisation
Deakin University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Elsevier BV
Date: 2016
Publisher: Elsevier BV
Date: 03-2023
Publisher: Elsevier BV
Date: 03-2020
Publisher: Elsevier BV
Date: 02-2020
Publisher: Elsevier BV
Date: 03-2019
Publisher: Informa UK Limited
Date: 18-12-2020
Publisher: Elsevier BV
Date: 11-2017
Publisher: Elsevier BV
Date: 11-2014
Publisher: Elsevier BV
Date: 10-2018
Publisher: Trans Tech Publications, Ltd.
Date: 11-2013
DOI: 10.4028/WWW.SCIENTIFIC.NET/MSF.773-774.281
Abstract: The flow curve behavior and microstructure evolution of commercially pure titanium (CP-Ti) through uniaxial hot compression was investigated at 850 °C and a strain rate of 0.1/s. Electron back scattered diffraction (EBSD) was employed to characterize the microstructure and crystallographic texture development for different thermomechanical conditions. The stress-strain curves of CP-Ti alloy under hot compression displayed a typical flow behavior of metals undergoing dynamic recrystallization (DRX), which resulted in grain refinement. The critical strain for the onset of DRX was 0.13 using the double differentiation analysis technique. It was also revealed that the texture was markably altered during hot deformation.
Publisher: Elsevier BV
Date: 2016
Publisher: American Medical Association (AMA)
Date: 07-2022
DOI: 10.1001/JAMANEUROL.2022.1269
Abstract: Women with epilepsy frequently need antiseizure medication (ASM) to prevent seizures in pregnancy. Risk of neurodevelopmental disorders after prenatal exposure to AMSs is uncertain. To determine whether children exposed prenatally to ASMs in monotherapy and duotherapy have increased risk of neurodevelopmental disorders. The Nordic register-based study of antiepileptic drugs in pregnancy (SCAN-AED) is a population-based cohort study using health register and social register data from Denmark, Finland, Iceland, Norway, and Sweden (1996-2017 analysis performed February 2022). From 4 702 774 alive-born children with available mother-child identities and maternal prescription data, this study included 4 494 926 participants. Children from a multiple pregnancy or with chromosomal disorders or uncertain pregnancy length were excluded (n = 207 848). Prenatal exposure to ASM determined from maternal prescription fills between last menstrual period and birth. We estimated cumulative incidence at age 8 years in exposed and unexposed children. Cox regression adjusted for potential confounders yielded adjusted hazard ratios (aHRs) with 95% CIs for autism spectrum disorder (ASD), intellectual disability (ID), or any neurodevelopmental disorder (ASD and/or ID). A total of 4 494 926 children were included 2 306 993 (51.3%) were male, and the median (IQR) age at end of follow-up was 8 (4.0-12.1) years. Among 21 634 unexposed children of mothers with epilepsy, 1.5% had a diagnosis of ASD and 0.8% (numerators were not available because of personal data regulations in Denmark) of ID by age 8 years. In same-aged children of mothers with epilepsy exposed to topiramate and valproate monotherapy, 4.3% and 2.7%, respectively, had ASD, and 3.1% and 2.4% had ID. The aHRs for ASD and ID after topiramate exposure were 2.8 (95% CI, 1.4-5.7) and 3.5 (95% CI, 1.4-8.6), respectively, and after valproate exposure were 2.4 (95% CI, 1.7-3.3) and 2.5 (95% CI, 1.7-3.7). The aHRs were elevated with higher ASM doses compared with children from the general population. The duotherapies levetiracetam with carbamazepine and lamotrigine with topiramate were associated with increased risks of neurodevelopmental disorders in children of women with epilepsy: levetiracetam with carbamazepine: 8-year cumulative incidence, 5.7% aHR, 3.5 95% CI, 1.5-8.2 lamotrigine with topiramate: 8-year cumulative incidence, 7.5% aHR, 2.4 95% CI, 1.1-4.9. No increased risk was associated with levetiracetam with lamotrigine (8-year cumulative incidence, 1.6% aHR, 0.9 95% CI, 0.3-2.5). No consistently increased risks were observed for neurodevelopmental disorders after prenatal exposure to monotherapy with lamotrigine, levetiracetam, carbamazepin, oxcarbazepine, gapapentin, pregabalin, clonazepam, or phenobarbital. In this cohort study, prenatal exposure to topiramate, valproate, and several duotherapies were associated with increased risks of neurodevelopmental disorders.
Publisher: Elsevier BV
Date: 10-2013
Publisher: Trans Tech Publications, Ltd.
Date: 23-05-2014
DOI: 10.4028/WWW.SCIENTIFIC.NET/MSF.783-786.679
Abstract: The microstructure evolution of martensitic Ti-6Al-4V alloy was investigated through uniaxial hot compression at 700°C and a strain rate of 10 -3 s -1 . A combination of scanning electron microscopy observation in conjunction with high resolution electron back scattered diffraction (EBSD) was used to characterize the microstructure in detail. The development of the microstructure displayed continuous fragmentation of martensitic laths with increasing strain (i.e. continuous dynamic recrystallization), concurrently with decomposition of supersaturated martensite resulting in the formation of equiaxed grains. At a strain of 0.8, an ultrafine equiaxed grained structure with mostly high angle grain boundaries was successfully obtained. The current work proposes a novel approach to produce equiaxed ultrafine grains in a Ti-6Al-4V alloy through thermomechanical processing of a martensitic starting microstructure.
Publisher: Elsevier BV
Date: 12-2022
Publisher: Elsevier BV
Date: 10-2021
Publisher: Elsevier BV
Date: 11-2018
Publisher: Springer Science and Business Media LLC
Date: 08-08-2014
Publisher: Elsevier BV
Date: 12-2017
Publisher: Elsevier BV
Date: 12-2017
Publisher: Springer Science and Business Media LLC
Date: 23-06-2016
Publisher: Elsevier BV
Date: 07-2019
Publisher: Springer Science and Business Media LLC
Date: 06-11-2015
Publisher: Springer Science and Business Media LLC
Date: 26-02-2018
Publisher: Elsevier BV
Date: 04-2022
Publisher: Elsevier BV
Date: 08-2022
Publisher: Elsevier BV
Date: 06-2022
Publisher: Elsevier BV
Date: 05-2017
Publisher: Springer Science and Business Media LLC
Date: 19-02-2014
Publisher: Elsevier BV
Date: 10-2021
Publisher: Elsevier BV
Date: 06-2019
Publisher: Springer Science and Business Media LLC
Date: 08-07-2019
Publisher: Elsevier BV
Date: 03-2023
Publisher: Elsevier BV
Date: 07-2021
Publisher: Springer Science and Business Media LLC
Date: 02-2009
Publisher: Springer Science and Business Media LLC
Date: 23-11-2022
No related grants have been discovered for Qi Chao.